Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYT-510 in Generalized Anxiety Disorder
NCT07478744Phase 2Recruiting
- Sponsor
- Synendos Therapeutics
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYT-510 in generalized anxiety disorder (GAD), sponsored by Synendos Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
SYT-510
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07478744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478744.